<DOC>
	<DOC>NCT00116896</DOC>
	<brief_summary>This is a Phase I, open-label, dose escalation, study of the combination of cisplatin and OSI-7904L given on Day 1 every 21 days in patient who have advanced solid tumors.</brief_summary>
	<brief_title>Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Cisplatin</mesh_term>
	<criteria>18 years of age or older Advanced and/or metastatic solid tumor for which no effective therapy is available ECOG performance status 02 Adequate bone marrow, hepatic and renal function Patients with active or uncontrolled infections Neurotoxicity &gt;= Grade 2 Symptomatic brain metastases which are not stable</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2003</verification_date>
</DOC>